Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15496701 | 0.86 | L3MBTL1 (0.40) | CA12CA2CA9ALDH1A1HPGD | |
| SCHEMBL22644635 | 0.85 | PRMT3 (0.31) | — | |
| SCHEMBL15221544 | 0.83 | CA12 (0.36) | CA12CA2CA9ALDH1A1HPGD | |
| SCHEMBL9887118 | 0.82 | HDAC3 (0.32) | — | |
| SCHEMBL19112567 | 0.80 | L3MBTL1 (0.36) | CA12CA2CA9ALDH1A1HPGD | |
| SCHEMBL887936 | 0.80 | — | — | |
| SCHEMBL11986884 | 0.78 | CA12 (0.41) | CA12CA2CA9ALDH1A1HPGD | |
| SCHEMBL15617402 | 0.77 | — | — | |
| SCHEMBL12675357 | 0.77 | MVD (0.33) | — | |
| SCHEMBL19601268 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023200893-A1 | SMALL MOLECULE ENHANCERS OF ANTISENSE OLIGO ACTIVITY | OREGON STATE UNIVERSITY (US) | 2023-10-19 | — | — | WO | disclosed |
| US-10238753-B2 | Antisense conjugates for decreasing expression of DMPK | VALERION THERAPEUTICS, LLC (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180021449-A1 | ANTISENSE CONJUGATES FOR DECREASING EXPRESSION OF DMPK | VALERION THERAPEUTICS, LLC | 2018-01-25 | — | — | US | disclosed |
| US-20180021449-A1 | ANTISENSE CONJUGATES FOR DECREASING EXPRESSION OF DMPK | VALERION THERAPEUTICS, LLC | 2018-01-25 | — | — | US | disclosed |
| EP-1747024-B1 | DNA VIRUS MICRORNA AND METHODS FOR INHIBITING SAME | UNIV ROCKEFELLER (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9610362-B2 | Antisense conjugates for decreasing expression of DMPK | VALERION THERAPEUTICS, LLC (US) | 2017-04-04 | — | — | US | disclosed |
| US-9610362-B2 | Antisense conjugates for decreasing expression of DMPK | VALERION THERAPEUTICS, LLC (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160331814-A1 | Col 11A1 AND NOVEL FRAGMENT THEREOF FOR REGULATION OF BONE MINERALIZATION | BOISE STATE UNIVERSITY | 2016-11-17 | — | — | US | disclosed |
| US-20160331814-A1 | Col 11A1 AND NOVEL FRAGMENT THEREOF FOR REGULATION OF BONE MINERALIZATION | BOISE STATE UNIVERSITY | 2016-11-17 | — | — | US | disclosed |
| US-9212360-B2 | Human micrornas and methods for inhibiting same | THE ROCKEFELLER UNIVERSITY (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2327710-A1 | Anti-microRNA oligonucleotide molecules | THE ROCKEFELLER UNIVERSITY (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7943756-B2 | Anti-microRNA oligonucleotide molecules | ROCKEFELLER UNIVERSITY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100286385-A1 | Anti-MicroRNA Oligonucleotide Molecules | ROCKEFELLER UNIVERSITY (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100273255-A1 | Human micrornas and methods for inhibiting same | THE ROCKEFELLER UNIVERSITY | 2010-10-28 | — | — | US | disclosed |
| US-7772389-B2 | Inhibiting ribonucleoprotein particles (miRNPs) activity in a cell | ROCKEFELLER UNIVERSITY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090275729-A1 | MICRORNA AND METHODS FOR INHIBITING SAME | THE ROCKEFELLER UNIVERSITY (US) | 2009-11-05 | — | — | US | disclosed |
| US-7485421-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST GMBH (DE) | 2009-02-03 | — | — | US | disclosed |
| US-7416842-B2 | Isolated nucleic acid molecule comprising the sequence of a DNA virus microRNA; Epstein barr virus; inhibiting microRNP activity in a cell | THE ROCKEFELLER UNIVERSITY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7365058-B2 | MicroRNA and methods for inhibiting same | THE ROCKEFELLER UNIVERSITY (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070287179-A1 | Inhibiting ribonucleoprotein particles (miRNPs) activity in a cell | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331814-A1 | Col 11A1 AND NOVEL FRAGMENT THEREOF FOR REGULATION OF BONE MINERALIZATION | COL14A1, COL2A1, COL1A1 | CA12 745/4885CA2 708/4885CA9 778/4885 |
| US-10238753-B2 | Antisense conjugates for decreasing expression of DMPK | MBNL1, DMPK, MTPN | CA12 4829/4885CA2 4809/4885CA9 4769/4885 |
| US-20180021449-A1 | ANTISENSE CONJUGATES FOR DECREASING EXPRESSION OF DMPK | MBNL1, DMPK, MTPN | CA12 4829/4885CA2 4809/4885CA9 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.